See more : Landis+Gyr Group AG (LAND.SW) Income Statement Analysis – Financial Results
Complete financial analysis of Endo International plc (ENDP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Endo International plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Rorze Corporation (6323.T) Income Statement Analysis – Financial Results
- Jiangsu Yangdian Science & Technology Co. Ltd. (301012.SZ) Income Statement Analysis – Financial Results
- Brooks Macdonald Group plc (BRK.L) Income Statement Analysis – Financial Results
- Proton Motor Power Systems Plc (PPS.L) Income Statement Analysis – Financial Results
- Integrated Business Systems & Services, Inc. (IBSS) Income Statement Analysis – Financial Results
Endo International plc (ENDP)
About Endo International plc
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.99B | 2.90B | 2.91B | 2.95B | 3.47B | 4.01B | 3.27B | 2.88B | 2.62B | 3.03B | 2.73B | 1.72B | 1.46B | 1.26B | 1.09B | 909.66M | 820.16M | 615.10M | 595.61M | 398.97M | 251.98M | 197.43M | 138.55M | 108.37M |
| Cost of Revenue | 1.22B | 1.44B | 1.57B | 1.63B | 2.23B | 2.63B | 2.08B | 1.40B | 1.04B | 1.26B | 1.07B | 504.76M | 375.06M | 267.24M | 217.37M | 201.42M | 186.35M | 140.99M | 135.67M | 98.86M | 74.89M | 61.81M | 58.26M | 54.73M |
| Gross Profit | 1.77B | 1.46B | 1.35B | 1.32B | 1.24B | 1.38B | 1.19B | 1.48B | 1.58B | 1.77B | 1.66B | 1.21B | 1.09B | 993.30M | 868.24M | 708.24M | 633.81M | 474.11M | 459.94M | 300.12M | 177.09M | 135.62M | 80.28M | 53.64M |
| Gross Profit Ratio | 59.21% | 50.31% | 46.15% | 44.63% | 35.76% | 34.29% | 36.50% | 51.32% | 60.28% | 58.34% | 60.98% | 70.59% | 74.33% | 78.80% | 79.98% | 77.86% | 77.28% | 77.08% | 77.22% | 75.22% | 70.28% | 68.69% | 57.95% | 49.50% |
| Research & Development | 148.56M | 158.90M | 130.73M | 185.83M | 172.07M | 183.37M | 102.20M | 154.20M | 142.47M | 226.12M | 182.29M | 144.53M | 185.32M | 110.21M | 138.26M | 82.81M | 88.31M | 50.55M | 51.02M | 56.82M | 38.99M | 26.01M | 9.37M | 5.89M |
| General & Administrative | 0.00 | 698.51M | 632.42M | 646.04M | 629.87M | 770.73M | 741.30M | 795.86M | 0.00 | 0.00 | 0.00 | 18.98M | 93.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 861.76M | 698.51M | 632.42M | 646.04M | 629.87M | 770.73M | 741.30M | 795.86M | 0.00 | 0.00 | 0.00 | 18.98M | 93.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 849.34M | 898.85M | 858.17M | 547.61M | 348.36M | 496.15M | 412.76M | 388.86M | 232.26M | 194.63M | 306.62M | 157.71M | 165.99M | 85.40M | 51.23M | 32.91M |
| Operating Expenses | 1.01B | 857.41M | 763.15M | 831.86M | 801.94M | 954.10M | 843.50M | 950.06M | 991.81M | 1.12B | 1.04B | 711.11M | 626.76M | 606.36M | 551.01M | 471.66M | 320.57M | 245.18M | 357.65M | 214.53M | 204.99M | 111.41M | 60.60M | 38.81M |
| Cost & Expenses | 2.23B | 2.30B | 2.33B | 2.46B | 3.03B | 3.59B | 2.92B | 2.35B | 2.03B | 2.39B | 2.11B | 1.22B | 1.00B | 873.59M | 768.38M | 673.08M | 506.92M | 386.17M | 493.32M | 313.39M | 279.88M | 173.21M | 118.87M | 93.54M |
| Interest Income | 0.00 | 4.17M | 19.95M | 13.19M | 6.47M | 3.72M | 5.69M | 4.05M | 1.33M | 406.00K | 599.00K | 1.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 562.35M | 537.11M | 558.68M | 534.85M | 494.69M | 456.40M | 378.90M | 231.16M | 174.93M | 183.24M | 148.62M | 47.96M | 37.72M | 8.35M | 117.00K | 0.00 | 0.00 | 0.00 | 258.00K | 4.39M | 10.96M | 15.12M | 0.00 | 0.00 |
| Depreciation & Amortization | 457.10M | 518.81M | 612.86M | 723.71M | 983.77M | 983.31M | 632.76M | 331.65M | 255.66M | 285.52M | 237.41M | 108.40M | 99.88M | 49.91M | 16.29M | 17.85M | 15.88M | 11.02M | 6.67M | 3.53M | 58.29M | 28.86M | 8.31M | 7.37M |
| EBITDA | 472.85M | 472.97M | 764.59M | 250.02M | -807.27M | -2.61B | -300.40M | -560.34M | -278.82M | -325.14M | 683.28M | 549.04M | 497.26M | 460.46M | 369.66M | 251.58M | 340.12M | 242.12M | 115.93M | 68.82M | 28.95M | -119.04M | 13.64M | 7.57M |
| EBITDA Ratio | 15.80% | 33.27% | 26.24% | 8.48% | -23.27% | -65.02% | -49.59% | -19.48% | -10.65% | -10.74% | 25.03% | 31.99% | 34.04% | 36.53% | 34.05% | 27.66% | 41.47% | 39.36% | 19.46% | 17.25% | 11.49% | -60.30% | 9.85% | 6.99% |
| Operating Income | 15.75M | 603.16M | 581.87M | -469.13M | -960.07M | -3.47B | -933.48M | -896.94M | -425.63M | -551.73M | 508.37M | 465.37M | 390.02M | 387.47M | 317.23M | 210.53M | 313.25M | 228.94M | 109.26M | 65.29M | -27.90M | 24.22M | 19.68M | 14.83M |
| Operating Income Ratio | 0.53% | 20.78% | 19.97% | -15.92% | -27.68% | -86.57% | -28.56% | -31.17% | -16.26% | -18.22% | 18.62% | 27.12% | 26.70% | 30.74% | 29.22% | 23.14% | 38.19% | 37.22% | 18.34% | 16.36% | -11.07% | 12.27% | 14.20% | 13.69% |
| Total Other Income/Expenses | -562.35M | -629.67M | -926.78M | -469.70M | -522.94M | -452.34M | -1.14B | -228.76M | -133.94M | -189.86M | -156.68M | -44.67M | -30.36M | 14.73M | 36.02M | 23.21M | 11.00M | 2.16M | -258.00K | -4.39M | -10.96M | -187.24M | -14.35M | -14.45M |
| Income Before Tax | -546.60M | -26.52M | -344.90M | -938.83M | -1.48B | -3.92B | -1.44B | -1.13B | -559.57M | -741.58M | 351.69M | 420.70M | 359.66M | 402.20M | 353.25M | 233.73M | 324.24M | 231.10M | 109.00M | 60.89M | -38.86M | -163.02M | 5.33M | 382.00K |
| Income Before Tax Ratio | -18.26% | -0.91% | -11.83% | -31.86% | -42.75% | -97.85% | -43.99% | -39.13% | -21.38% | -24.50% | 12.88% | 24.51% | 24.62% | 31.91% | 32.54% | 25.69% | 39.53% | 37.57% | 18.30% | 15.26% | -15.42% | -82.57% | 3.85% | 0.35% |
| Income Tax Expense | 22.48M | -273.98M | 15.68M | 22.94M | -250.29M | -700.08M | -1.14B | -401.84M | -24.07M | -53.56M | 109.63M | 133.68M | 93.32M | 140.46M | 125.81M | 95.90M | 121.95M | 87.79M | 39.21M | 30.08M | -3.75M | -6.18M | 2.07M | -14.45M |
| Net Income | -569.08M | 183.94M | -422.64M | -1.03B | -2.04B | -3.35B | -1.50B | -721.32M | -685.34M | -740.34M | 187.61M | 259.01M | 266.34M | 261.74M | 227.44M | 137.84M | 202.30M | 143.31M | 69.79M | 30.81M | -36.54M | -156.84M | 3.26M | 201.00K |
| Net Income Ratio | -19.01% | 6.34% | -14.50% | -35.00% | -58.68% | -83.46% | -45.74% | -25.07% | -26.19% | -24.45% | 6.87% | 15.09% | 18.23% | 20.76% | 20.95% | 15.15% | 24.67% | 23.30% | 11.72% | 7.72% | -14.50% | -79.44% | 2.35% | 0.19% |
| EPS | -2.44 | 0.79 | -1.87 | -4.61 | -9.12 | -15.03 | -6.73 | -4.69 | -5.94 | -6.68 | 1.60 | 2.23 | 2.28 | 2.12 | 1.70 | 1.03 | 1.53 | 1.09 | 0.54 | 0.30 | -0.40 | -1.97 | 0.05 | 0.00 |
| EPS Diluted | -2.44 | 0.79 | -1.87 | -4.61 | -9.12 | -15.03 | -6.73 | -4.69 | -5.94 | -6.40 | 1.55 | 2.20 | 2.27 | 2.12 | 1.69 | 1.03 | 1.52 | 1.08 | 0.53 | 0.30 | -0.40 | -1.97 | 0.05 | 0.00 |
| Weighted Avg Shares Out | 232.79M | 233.65M | 226.05M | 223.96M | 223.20M | 222.65M | 222.12M | 153.91M | 115.35M | 110.79M | 117.16M | 116.06M | 117.06M | 123.25M | 133.90M | 133.18M | 132.24M | 131.81M | 128.42M | 102.06M | 91.51M | 79.45M | 71.33M | 71.31M |
| Weighted Avg Shares Out (Dil) | 232.79M | 233.65M | 226.05M | 223.96M | 223.20M | 222.65M | 222.12M | 153.91M | 115.35M | 115.72M | 121.18M | 117.95M | 117.52M | 123.72M | 134.53M | 133.91M | 133.29M | 132.72M | 132.44M | 102.13M | 91.51M | 79.45M | 71.33M | 71.31M |
5 Stocks Investors Must Buy for Relative Price Strength
Endo International (ENDP) Crossed Above the 200-Day Moving Average: What That Means for Investors
Endo International plc (ENDP) CEO Blaise Coleman on Q3 2021 Results - Earnings Call Transcript
Endo (ENDP) Beats Q3 Earnings & Sales Estimates, Raises View
Best Penny Stocks to Buy Today? 3 to Watch in Early November
Endo: A Win In California But Equity Value Still A Question
5 Top Penny Stocks Analysts Say To Buy With 119%-430% Price Targets
Endo to Announce Third Quarter 2021 Financial Results
7 Best Penny Stocks to Buy on the Nasdaq for October
Endo Reaches Agreement in Principle to Settle Louisiana Governmental Opioid Cases and Claims
Source: https://incomestatements.info
Category: Stock Reports